Search

Arnold S Lippa

from Ridgewood, NJ
Age ~78
Get Report
Also known as:
Arnold Linda Lippa, Arnold L Lippa, Arnold F Lippa, Arnold Arnold, Lippa Arnold
Phone and address:
325 Greenway Rd, Ridgewood, NJ 07450
(201) 493-9061
Related to:
Linda LippaBlanche MorgenrothLynda Morgenroth, 77Manfred Morgenroth
Connected to:
Jeffrey M Lippa, 61Justin J Lippa, 85Louis J Lippa, 38John A Lippai, 57Joshua A Lippai, 37Sandra Lippan, 44Alicia M Lippard, 63Ann Lippard, 63Cathy S Lippard, 67Daniel E Lippard, 59

Arnold Lippa Phones & Addresses

  • 325 Greenway Rd, Ridgewood, NJ 07450 (201) 493-9061
  • 345 Crest Rd, Ridgewood, NJ 07450
  • Franklin Lakes, NJ
  • East Hampton, NY
  • 1 5Th St, New York, NY 10001
  • 433 Hackensack Ave, Hackensack, NJ 07601
  • Berlin, NJ

Work

Company: Cortex pharmaceuticals Mar 2013 Position: Chief executive officer and chairman

Education

Degree: Ph.D. School / High School: University of Pittsburgh 1969 to 1973 Specialities: Neurobiology

Skills

Biotechnology • Pharmaceutical Industry • Mergers & Acquisitions • Neuroscience • Lifesciences • Entrepreneurship • Biopharmaceuticals • Drug Development

Industries

Biotechnology

Resumes

Resumes

Arnold Lippa Photo 1

Chief Executive Office And Chairman At Cortex Pharmaceuticals

View page
Position:
Chief Executive Officer and Chairman at Cortex Pharmaceuticals, Executive Chairman at Xintria Pharmaceutical Corp., Senior Managing Director and Principal at Aurora Capital LLC, Principal at Atypical Biocapital Management LLC
Location:
Greater New York City Area
Industry:
Biotechnology
Work:
Cortex Pharmaceuticals since Mar 2013
Chief Executive Officer and Chairman
Xintria Pharmaceutical Corp. since Jan 2007
Executive Chairman
Aurora Capital LLC since 2005
Senior Managing Director and Principal
Atypical Biocapital Management LLC since 2005
Principal
DOV Pharmaceutical 1996 - 2004
CEO
Education:
University of Pittsburgh 1969 - 1973
Ph.D., Neurobiology Rutgers, The State University of New Jersey-New Brunswick 1965 - 1969
BS, Psychobiology
Skills:
Biotechnology
Pharmaceutical Industry
Mergers & Acquisitions
Neuroscience
Lifesciences
Entrepreneurship
Biopharmaceuticals
Drug Development

Business Records

Name / Title
Company / Classification
Phones & Addresses
Arnold Lippa
President
CORTEX PHARMACEUTICALS, INC
Manufacturing Pharmaceutical Preparations · Mfg Pharmaceutical Preparations · Pharmaceutical Preparation Manufacturing · Research & Development in Biotechnology · Bolt, Nut, Screw, Rivet, and Washer Manufacturing
325 Greenway Rd, Ridgewood, NJ 07450
15241 Barranca Pkwy, Irvine, CA 92618
15231 Barranca Pkwy, Irvine, CA 92618
(949) 727-3157, (949) 727-3657

Publications

Us Patents

(+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As An Anti-Depressant Agent

View page
US Patent:
6372919, Apr 16, 2002
Filed:
Jan 11, 2001
Appl. No.:
09/758883
Inventors:
Arnold Stan Lippa - Ridgewood NJ
Joseph William Epstein - Monroe NY
Assignee:
DOV Pharmaceutical, Inc. - Hackensack NJ
International Classification:
C07D20952
US Classification:
548452, 514412
Abstract:
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing depression in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (-)-enantiomer.

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As A Dopamine-Reuptake

View page
US Patent:
6569887, May 27, 2003
Filed:
Aug 24, 2001
Appl. No.:
09/939071
Inventors:
Arnold Stan Lippa - Ridgewood NJ
Joseph William Epstein - Monroe NY
Assignee:
Dov Pharmaceuticals Inc. - Hackensack NJ
International Classification:
A61K 31403
US Classification:
514412, 548452
Abstract:
The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinsons disease, a tic disorder, or an addictive disorder. The (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As A Dopamine-Reuptake Inhibitor

View page
US Patent:
6716868, Apr 6, 2004
Filed:
Apr 29, 2003
Appl. No.:
10/425545
Inventors:
Arnold Stan Lippa - Ridgewood NJ
Joseph William Epstein - Monroe NY
Assignee:
DOV Pharmaceutical Inc - Hackensack NJ
International Classification:
A61K 31403
US Classification:
514412, 548452
Abstract:
The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinsons disease, a tic disorder, or an addictive disorder. The (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(−)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As A Dopamine-Reuptake Inhibitor

View page
US Patent:
7041835, May 9, 2006
Filed:
Jan 23, 2004
Appl. No.:
10/764375
Inventors:
Arnold Stan Lippa - Ridgewood NJ, US
Joseph William Epstein - Monroe NY, US
Assignee:
Dor Pharmaceutical, Inc. - Hackensack NJ
International Classification:
C07D 209/02
US Classification:
548452
Abstract:
The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As A Dopamine-Reuptake Inhibitor

View page
US Patent:
7081471, Jul 25, 2006
Filed:
Jan 23, 2004
Appl. No.:
10/764371
Inventors:
Arnold Stan Lippa - Ridgewood NJ, US
Joseph William Epstein - Monroe NJ, US
Assignee:
DOV Pharmaceutical, Inc. - Hachensack NJ
International Classification:
A61K 31/40
US Classification:
514412
Abstract:
The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

(+)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions And Uses Thereof

View page
US Patent:
7098229, Aug 29, 2006
Filed:
Jan 11, 2002
Appl. No.:
10/466457
Inventors:
Arnold S. Lippa - Ridgewood NJ, US
Joseph W. Epstein - Monroe NY, US
Assignee:
DOV Pharmaceutical, Inc. - Hackensack NJ
International Classification:
A61K 31/403
C07D 209/52
US Classification:
514412, 548452
Abstract:
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating of or preventing relapse of depression, anxiety disorders, eating disorders, or urinary incontinence in a patient comprising administering (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (−)-enantiomer.

(-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane, Compositions Thereof, And Uses As A Dopamine-Reuptake Inhibitor

View page
US Patent:
7098230, Aug 29, 2006
Filed:
Jan 23, 2004
Appl. No.:
10/764373
Inventors:
Arnold Stan Lippa - Ridgewood NJ, US
Joseph William Epstein - Monroe NY, US
Assignee:
DOV Pharmaceutical, Inc. - Somerset NJ
International Classification:
A61K 31/40
US Classification:
514412
Abstract:
The present invention relates to (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3. 1. 0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

Extended Release Formulation Of Diltiazem Hydrochloride

View page
US Patent:
20020172694, Nov 21, 2002
Filed:
May 15, 2001
Appl. No.:
09/855218
Inventors:
Arnold Lippa - Ridgewood NJ, US
Assignee:
DOV Pharmaceutical, Inc. - Hackensack NJ
International Classification:
A61K009/00
US Classification:
424/400000
Abstract:
An extended release formulation of diltiazem which is suitable for once-daily oral administration comprises a quantity of a quick release preparation of diltiazem or a pharmaceutically active salt thereof, mixed with a quantity of a slow release (or delayed release) preparation of diltiazem or a pharmaceutically active salt thereof. The quick release preparation used obtains a maximal release of diltiazem within approximately 1-2 hours after administration, and then falls toward baseline levels. The delayed release preparation individually shows a maximal release of diltiazem at between approximately 6-8 hours after administration. The formulation containing the two preparation achieves a maximal release of diltiazem approximately within 1-2 hours after administration, and the levels of released diltiazem remain near these maximal levels for approximately another 12 hours after administration, compared to other extended release formulations of diltiazem (referred to herein as slow or delayed release preparations) which achieve maximal release approximately 9 hours after oral administration. The preferred embodiment is a capsule containing the formulation, which, based upon the total quantity of drug in the formulation rather than total weight of the formulation, comprises equal weights of the quick release and slow release forms of diltiazem, and preferably up to 50 percent by weight of each of the slow (or delayed) and quick release preparation of diltiazem. The present invention has application for combinations of other preparations of quick release and slow or delayed release pharmaceuticals.
Control profile
Arnold S Lippa from Ridgewood, NJ, age ~78 Get Report